On Thursday, Indivior (NASDAQ: INDV), the British drugmaker, cut its 2024 net revenue forecast for the second time in three months, citing lower-than-expected revenues from its Sublocade treatment for opioid use disorder, sending shares 15% lower.
The company said that revenues from its opioid addiction treatment have been negatively impacted by the rapid adoption of Brixadi, a competing drug developed by Swedish pharmaceutical firm Camurus.
Indivior no longer expects Sublocade will exit 2025 at a $1 billion net revenue run rate.
Shares of Indivior (NASDAQ: INDV) were down 15% to 613 pence – their lowest since 2021 – at 1116 GMT.
The London-listed company now expects revenue to be between $1.13 billion and $1.17 billion for the full year, down from a prior range of $1.15 billion to $1.22 billion.
(Source: ReutersReuters)
